MMTZF MindMaze Therapeutics Holding SA IFRS Annual reports only
Pharmaceutical Preparations · OTC · SEC CIK 1854078 · Reporting currency CHF · Fiscal year ends 12/31
Financial factors as of 2023-12-31 (FY2023), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CHF | FY2023*2023-12-31 | FY2022*2022-12-31 | FY2021*2021-12-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | 6.33M | 7.11M | 4.49M |
| R&D expense | 1.33M | 12.39M | 19.02M |
| Operating income | -110.83M | -52.04M | -34.31M |
| Interest expense | 949,000 | 2.29M | 1.32M |
| Pretax income | -111.68M | -54.32M | -35.52M |
| Income tax | -13.50M | -3.53M | -820,000 |
| Net income | -98.18M | -50.79M | -34.70M |
| EBITDA | -107.51M | -48.18M | -32.27M |
| EPS (basic) | -8.35 | -4.80 | -0.01 |
| EPS (diluted) | -8.35 | -4.80 | -0.01 |
| Weighted avg. shares (diluted) | 11.75M | 10.57M | 3.59B |
| Balance sheet | |||
| Cash & equivalents | 14.56M | 19.24M | 44.76M |
| Short-term investments | 9,000 | 28,000 | 28,000 |
| Receivables | 1.17M | 1.32M | 1.30M |
| Inventory | 557,000 | 227,000 | 391,000 |
| Current assets | 18.30M | 22.58M | 54.97M |
| PP&E, netmay include right-of-use assets (IFRS) | 397,000 | 49,000 | 38,000 |
| Intangibles | 54.41M | 162.91M | 192.30M |
| Total assets | 76.39M | 188.80M | 251.62M |
| Current liabilities | 6.91M | 10.72M | 19.73M |
| Short-term debt | 337,000 | 372,000 | 95,000 |
| Long-term debt | 9,000 | 16,000 | 396,000 |
| Total debt | 346,000 | 388,000 | 491,000 |
| Total liabilities | 24.16M | 43.38M | 70.09M |
| Shareholders' equity | 52.23M | 145.42M | 181.53M |
| Net debt | -14.21M | -18.85M | -44.27M |
| Cash flow statement | |||
| Operating cash flow | -17.61M | -24.13M | -35.72M |
| Capital expenditure | 446,000 | 33,000 | — |
| Free cash flow | -18.06M | -24.16M | — |
| Investing cash flow | 8.70M | -8.00M | -30.26M |
| Financing cash flow | 4.05M | 6.42M | 67.69M |
| Depreciation & amortization | 3.32M | 3.86M | 2.04M |
| Stock-based compensation | 814,000 | 2.19M | 1.14M |
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· Amounts are in the company's reporting currency, CHF, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.